Search

Author/Creator Dummer, Reinhard

141. NRASQ61K melanoma tumor formation is reduced by p38‐MAPK14 activation in zebrafish models and NRAS‐mutated human melanoma cells. (24th September 2020)

Authors:
Banik, Ishani; Cheng, Phil F.; Dooley, Christopher M.; Travnickova, Jana; Merteroglu, Munise; Dummer, Reinhard; Patton, Elizabeth E.; Busch‐Nentwich, Elisabeth M.; Levesque, Mitchell P.
Journal:
Pigment cell & melanoma research
Issue:
Volume 34:Number 2(2021)
Page Start:
150
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

142. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Issue 10 (October 2018)

Authors:
Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A;...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 10(2018)
Page Start:
1315
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

143. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2019)

Authors:
Schadendorf, Dirk; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Lesimple, Thierry; Plummer, Ruth; Schachter, Jacob; Dasgupta, Kohinoor; Manson, S...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 5(2019)
Page Start:
701
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

144. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. (July 2020)

Authors:
Dummer, Reinhard; Prince, Henry M.; Whittaker, Sean; Horwitz, Steven M.; Kim, Youn H.; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Eradat, Herbert; Pinter-Brown, Lauren; Sanches, Jose A.; Ortiz-Romero, Pablo L.; Akilov, Oleg E.; Geskin, Larisa; Huen, Auris; Walewski...
Journal:
European journal of cancer
Issue:
Volume 133(2020)
Page Start:
120
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

147. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Issue 8 (August 2015)

Authors:
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentle...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
908
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

148. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Issue 8 (August 2015)

Authors:
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentle...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 8(2015:Aug.)
Page Start:
908
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

149. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Issue 10336 (30th April 2022)

Authors:
Luke, Jason J; Rutkowski, Piotr; Queirolo, Paola; Del Vecchio, Michele; Mackiewicz, Jacek; Chiarion-Sileni, Vanna; de la Cruz Merino, Luis; Khattak, Muhammad A; Schadendorf, Dirk; Long, Georgina V; Ascierto, Paolo A; Mandala, Mario; De Galitiis, Federica; Haydon, Andrew; Dummer, Reinhard; Grob, J...
Journal:
Lancet
Issue:
Volume 399:Issue 10336(2022)
Page Start:
1718
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

150. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Issue 11 (November 2022)

Authors:
Long, Georgina V; Luke, Jason J; Khattak, Muhammad A; de la Cruz Merino, Luis; Del Vecchio, Michele; Rutkowski, Piotr; Spagnolo, Francesco; Mackiewicz, Jacek; Chiarion-Sileni, Vanna; Kirkwood, John M; Robert, Caroline; Grob, Jean-Jacques; de Galitiis, Federica; Schadendorf, Dirk; Carlino, Matteo ...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 11(2022)
Page Start:
1378
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗